Open access
Jul 2026
Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells
The potential of bioengineered PD-L1 siRNA entities for NSCLC immunotherapy is demonstrated and their immunotherapeutic efficacy against non-small cell lung cancer (NSCLC) in vitro is defined.
N. Batra, Mei-Juan Tu, Su Guan et al.
· Non-Coding RNA · 0 citations